ANCHOR LEAD: A NEW RAPID ACCESS PROGRAM FOR TREATMENT DEVELOPMENT AT THE NATIONAL CANCER INSTITUTE IS BEARING FRUIT, ELIZABETH TRACEY REPORTS
New drugs and treatments don’t get to the clinic fast enough to benefit dying people. That’s been one vociferous criticism of the FDA for decades. Now a new program developed by the National Cancer Institute known by the acronym ‘RAID’ may help. Bill Nelson, director of the Kimmel Cancer Center at Johns Hopkins, describes the initiative.
NELSON: Oftentimes when these new treatments for cancer when they get manufactured and marketed are really in the province of the pharmaceutical and biotechnology industry. But there were so many discoveries percolating up that the pharma and biotech industries were not meeting that demand by developing enough of these drugs and so the National Cancer Institute came up with a way to manufacture and make some of these drugs in a prioritized way to fill that gap. And this is first one of these that has gone all the way to FDA approval, registration for marketing for a kind of a lymphoma, a peripheral T cell lymphoma. :30
Nelson is cautiously optimistic that as with this drug, the program will help circumvent time-consuming approval processes. At Johns Hopkins, I’m Elizabeth Tracey.